JPS6023084B2 - 代用血液 - Google Patents
代用血液Info
- Publication number
- JPS6023084B2 JPS6023084B2 JP54087910A JP8791079A JPS6023084B2 JP S6023084 B2 JPS6023084 B2 JP S6023084B2 JP 54087910 A JP54087910 A JP 54087910A JP 8791079 A JP8791079 A JP 8791079A JP S6023084 B2 JPS6023084 B2 JP S6023084B2
- Authority
- JP
- Japan
- Prior art keywords
- hemoglobin
- polyethylene glycol
- mol
- moles
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003633 blood substitute Substances 0.000 title claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 43
- 102000001554 Hemoglobins Human genes 0.000 claims description 43
- 239000002202 Polyethylene glycol Substances 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 9
- 229920001451 polypropylene glycol Polymers 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- -1 stearyl ester Chemical class 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- YZBOVSFWWNVKRJ-UHFFFAOYSA-M 2-butoxycarbonylbenzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1C([O-])=O YZBOVSFWWNVKRJ-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- XKXPBJBODVHDAW-UHFFFAOYSA-N 4-(4-amino-2-chlorophenyl)-3-chloroaniline Chemical compound ClC1=CC(N)=CC=C1C1=CC=C(N)C=C1Cl XKXPBJBODVHDAW-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101710169606 Hemoglobin-2 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
本発明は、修飾ヘモグロビンを酸素運搬物質として含有
する新規代用血液に関する。
する新規代用血液に関する。
従来、代用血液に使用する酸素運搬物質として膜成分を
含まないヘモグロビンを用いることは公知である（Ｓ．
Ｆ．Ｒａｂｉｎｅ「 ｅｔ．ａｌ、Ｊ．Ｅｘ．Ｍｅｄ．
、１２６、１１４２（１９６７））。
含まないヘモグロビンを用いることは公知である（Ｓ．
Ｆ．Ｒａｂｉｎｅ「 ｅｔ．ａｌ、Ｊ．Ｅｘ．Ｍｅｄ．
、１２６、１１４２（１９６７））。
ところが、ヘモグロビンは血管内に注入されると速やか
に腎臓あるいは肝臓等から代謝されることが知られてい
る。この問題を解決するためにヘモグロビンをグルタル
アルデヒドで相互結合させたもの（持閥昭５１−６３９
２０号公報）、ヘモグロビンをデキストラン（特開昭５
２一５１０１６号公報）若し〈はヒドロキシェチル澱粉
（西独公開２６１６０８６号）に結合せしめたものに提
案された。しかしこれらのものは例えば前者は酸素親和
性が強すぎるために末梢組織での酸素の受け渡しが行わ
れにくく、また後者は粘度が高いためにヘモグロビン濃
度を上げると好ましくない結果をもたらす場合が多い。
本発明者は、ヘモグ。
に腎臓あるいは肝臓等から代謝されることが知られてい
る。この問題を解決するためにヘモグロビンをグルタル
アルデヒドで相互結合させたもの（持閥昭５１−６３９
２０号公報）、ヘモグロビンをデキストラン（特開昭５
２一５１０１６号公報）若し〈はヒドロキシェチル澱粉
（西独公開２６１６０８６号）に結合せしめたものに提
案された。しかしこれらのものは例えば前者は酸素親和
性が強すぎるために末梢組織での酸素の受け渡しが行わ
れにくく、また後者は粘度が高いためにヘモグロビン濃
度を上げると好ましくない結果をもたらす場合が多い。
本発明者は、ヘモグ。
ビンと同程度の酸素運搬能力を有し、その血管内滞留時
間が十分長い代用血液用酸素運搬物質を開発すべく鋭意
検討した結果、ヘモグロビンと、ポリエチレングリコー
ル、ポリプロピレングリコールまたはエチレングリコー
ループロピレングリコール−共重合体との結合物（以下
、「疹節ヘモグロビン」という。）がその目的を達成す
ることを見出し本発明を完成した。前記ポリエチレング
リコール、ポリプロピレングリコールおよびエチレング
リコーループロピレングリコール共重合体は本明細書に
おいてモノメチルエーテル、モノセチルエーテル、モノ
オレイルェーテル等炭素数１乃至１６のアルコールによ
るエーテル化物、モノブチルェステル、モノステァリル
ェステル等炭素数２乃至１８の脂肪酸類によるェステル
化物、プロピルアミン、ステアリルアミン等炭素数１乃
至１８のァミン類による脱水ァミノ化物をも含む。これ
ら重合物を以下単に「本発明に使用する重合体」という
。本発明に使用する修飾ヘモグロビンは、生体内に存す
るヘモグロビンと安全性の高い本発明に使用する重合体
との結合物であるので安全な物質であり、酸素親和性が
へモグ。
間が十分長い代用血液用酸素運搬物質を開発すべく鋭意
検討した結果、ヘモグロビンと、ポリエチレングリコー
ル、ポリプロピレングリコールまたはエチレングリコー
ループロピレングリコール−共重合体との結合物（以下
、「疹節ヘモグロビン」という。）がその目的を達成す
ることを見出し本発明を完成した。前記ポリエチレング
リコール、ポリプロピレングリコールおよびエチレング
リコーループロピレングリコール共重合体は本明細書に
おいてモノメチルエーテル、モノセチルエーテル、モノ
オレイルェーテル等炭素数１乃至１６のアルコールによ
るエーテル化物、モノブチルェステル、モノステァリル
ェステル等炭素数２乃至１８の脂肪酸類によるェステル
化物、プロピルアミン、ステアリルアミン等炭素数１乃
至１８のァミン類による脱水ァミノ化物をも含む。これ
ら重合物を以下単に「本発明に使用する重合体」という
。本発明に使用する修飾ヘモグロビンは、生体内に存す
るヘモグロビンと安全性の高い本発明に使用する重合体
との結合物であるので安全な物質であり、酸素親和性が
へモグ。
ピンと同程度またはやや弱いために体内での酸素の受け
渡し１こは好ましく、また血管内滞留時間もヘモグロビ
ンの２〜４倍にのび、代用血液に用いるのに好ましい化
合物である。特に、ポリエチレングリコールと蛋白との
結合物は蛋白の抗原性を消失させ得ることが知られてお
り（芦原、他、化学の領域、３３（１）、４４（１９７
９））、本発明に使用する修飾ヘモグロビンは血管内に
おいて抗原となるおそれのない安全性の高い物質である
。本発明に使用するヘモグロビンはヒト、ウシ、ブタ、
ヒツジ、ウマ、イヌ、サル、ウサギ、ニワトリ等ヘモグ
ロビンを有する動物であればいずれであっても差支えな
い。
渡し１こは好ましく、また血管内滞留時間もヘモグロビ
ンの２〜４倍にのび、代用血液に用いるのに好ましい化
合物である。特に、ポリエチレングリコールと蛋白との
結合物は蛋白の抗原性を消失させ得ることが知られてお
り（芦原、他、化学の領域、３３（１）、４４（１９７
９））、本発明に使用する修飾ヘモグロビンは血管内に
おいて抗原となるおそれのない安全性の高い物質である
。本発明に使用するヘモグロビンはヒト、ウシ、ブタ、
ヒツジ、ウマ、イヌ、サル、ウサギ、ニワトリ等ヘモグ
ロビンを有する動物であればいずれであっても差支えな
い。
ヘモグロビンに結合する本発明に使用する重合体の分子
量は３００〜２００００、性能および粘度の点で好まし
くは７５０〜５０００である。
量は３００〜２００００、性能および粘度の点で好まし
くは７５０〜５０００である。
ヘモグロビンと本発明に使用する重合体とはどのような
方法により結合させてもよく、例えば臭化シアン等の縮
合剤を用いて直接に結合させたり、あるいは塩化シアヌ
ル、２・２′ージクロロベンジジン、Ｐ・Ｐ′−ジフル
オローｍ・ｍ′−ジニトロジフエニルスルフオン、２・
４−ジクロロニトロベンゼン等の化学結合剤により結合
させればよい。
方法により結合させてもよく、例えば臭化シアン等の縮
合剤を用いて直接に結合させたり、あるいは塩化シアヌ
ル、２・２′ージクロロベンジジン、Ｐ・Ｐ′−ジフル
オローｍ・ｍ′−ジニトロジフエニルスルフオン、２・
４−ジクロロニトロベンゼン等の化学結合剤により結合
させればよい。
ヘモグロビン１分子当り、本発明に使用する重合体は４
〜１５び分子程度が結合している。
〜１５び分子程度が結合している。
本発明に使用する修飾ヘモグロビンは、例えば次の如く
して調製することができる。｛１｝ ポリエチレングリ
コールと２〜５倍モル好ましくは３倍モルの臭化シアン
とをｐＨ９〜１０で反応させた後ゲル猿週、透析等の方
法により臭化シアンを除去する。
して調製することができる。｛１｝ ポリエチレングリ
コールと２〜５倍モル好ましくは３倍モルの臭化シアン
とをｐＨ９〜１０で反応させた後ゲル猿週、透析等の方
法により臭化シアンを除去する。
得られた物質にｐＨ７〜９好まし〈は７．５〜８で水溶
液中１／Ｉ０〜１／５０の音好ましくは１／１０ぴ音モ
ル程度のヘモグロビンとを反応せしめる。‘２１ 過剰
の炭酸ソーダを含むベンゼンにポリエチレングリコール
を加え、これと２〜５倍モル好ましくは３〜４倍モルの
塩化シアヌルとを反応させ生成したポリエチレングリコ
ール−４・６−ジクロル−Ｓ−トＩＪァジンを分離する
。
液中１／Ｉ０〜１／５０の音好ましくは１／１０ぴ音モ
ル程度のヘモグロビンとを反応せしめる。‘２１ 過剰
の炭酸ソーダを含むベンゼンにポリエチレングリコール
を加え、これと２〜５倍モル好ましくは３〜４倍モルの
塩化シアヌルとを反応させ生成したポリエチレングリコ
ール−４・６−ジクロル−Ｓ−トＩＪァジンを分離する
。
ｐＨ８〜９．５の緩衝液中ポリエチレングリコールー４
・６−ジクロル−Ｓ−トリアジンと１〜１／５０の音モ
ル好ましくは１／１０〜１／１０Ｍ音モルのヘモグロビ
ンとを反応せしめる。上記調製法は、ポリエチレングリ
コールに代えてポリプロピレングリコールまたはエチレ
ングリコーループロピレングリコール共重合体を用いて
も、同様に実施することが可能である。
・６−ジクロル−Ｓ−トリアジンと１〜１／５０の音モ
ル好ましくは１／１０〜１／１０Ｍ音モルのヘモグロビ
ンとを反応せしめる。上記調製法は、ポリエチレングリ
コールに代えてポリプロピレングリコールまたはエチレ
ングリコーループロピレングリコール共重合体を用いて
も、同様に実施することが可能である。
以下実施例により本発明を詳細に説明する。
実施例 １ポリエチレングリコ−ルモノメチルエーテル
（平均分子量７５０）２．５夕（０．００３モル）を４
０の‘の水に溶解し、これに５の‘のジキオサンに溶解
した１夕（０．００９５モル）の臭化シアンを氷冷化滴
下した。州ＮａＯＨによりＰＨ９〜１０に保ちつつ１時
間縄拝を続けた。ＩＮＨＣＩによりｐＨ７．５に調製し
たのち分子量５０瓜阻止のメンブランにより限外濠週を
行った。２０の‘まで濃縮したのちｐＨ７．５のリン酸
緩衝液３００の‘を加え再度２０Ｍまで濃縮した。
（平均分子量７５０）２．５夕（０．００３モル）を４
０の‘の水に溶解し、これに５の‘のジキオサンに溶解
した１夕（０．００９５モル）の臭化シアンを氷冷化滴
下した。州ＮａＯＨによりＰＨ９〜１０に保ちつつ１時
間縄拝を続けた。ＩＮＨＣＩによりｐＨ７．５に調製し
たのち分子量５０瓜阻止のメンブランにより限外濠週を
行った。２０の‘まで濃縮したのちｐＨ７．５のリン酸
緩衝液３００の‘を加え再度２０Ｍまで濃縮した。
氷冷下縄拝しつつ１０％ヘモグロビン溶液２０の上を加
え４℃に一夜放置した。ｐＨ６．０に平衡化したＣＭー
セフアデックス樹脂に反応液を通してヘモグロビンおよ
び生成物を吸着させた後ｐＨ６．８のリン酸緩衝液によ
り溶麹する画分を分離した。分子量５方阻止のメンブラ
ンにより限外櫨過を行い脱塩、濃縮後０．４＆メンブラ
ンにより猿過し、乾燥後、ポリエチレングリコ−ルモノ
メチルェーテルが結合したヘモグロビン３．５夕を得た
。ポリエチレングリコ‐ルモノメチルエーテルの置換度
は約１０であった。
え４℃に一夜放置した。ｐＨ６．０に平衡化したＣＭー
セフアデックス樹脂に反応液を通してヘモグロビンおよ
び生成物を吸着させた後ｐＨ６．８のリン酸緩衝液によ
り溶麹する画分を分離した。分子量５方阻止のメンブラ
ンにより限外櫨過を行い脱塩、濃縮後０．４＆メンブラ
ンにより猿過し、乾燥後、ポリエチレングリコ−ルモノ
メチルェーテルが結合したヘモグロビン３．５夕を得た
。ポリエチレングリコ‐ルモノメチルエーテルの置換度
は約１０であった。
実施例 ２
ポリエチレングリコ一ルモノメチルエーテル（平均分子
量７５０）７．５夕（０．０１モル）を５００の‘のベ
ンゼンに溶解し、炭酸ソーダ１０夕を加えた。
量７５０）７．５夕（０．０１モル）を５００の‘のベ
ンゼンに溶解し、炭酸ソーダ１０夕を加えた。
氷冷下、激しく鷹拝しつつ塩化シアヌル５．５夕（０．
０３モル）を加えた後、室温にて一夜縄拝した。炭酸ソ
ーダを猿過後、石油エーテル（沸点３０〜７０ｑｏ）１
そを加えると２−○ーメトキシポリェチレングリコール
−４・６ージクロロ−Ｓ−トリアジン（活性化ポリエチ
レングリコール）が沈澱した。この結晶を石油エーテル
でよく洗った後乾燥した（１１．５夕）。ヘモグロビン
０．５夕（０．００７７ミリモル）を１００泌のホゥ酸
緩衝液（ｐＨ９．２）に溶解した溶液に氷冷下上記活性
化ポリエチレングリコール１．７夕（１．８ミリモル）
を加えた。１時間氷冷下礎洋した後分子量１０方阻止メ
ンプランにより限外渡過を繰返し未反応ヘモグロビンお
よび活性化ポリエチレングリコ、一ルを猿別後乾燥する
ことにより修飾ヘモグロビン２．６夕を得た。
０３モル）を加えた後、室温にて一夜縄拝した。炭酸ソ
ーダを猿過後、石油エーテル（沸点３０〜７０ｑｏ）１
そを加えると２−○ーメトキシポリェチレングリコール
−４・６ージクロロ−Ｓ−トリアジン（活性化ポリエチ
レングリコール）が沈澱した。この結晶を石油エーテル
でよく洗った後乾燥した（１１．５夕）。ヘモグロビン
０．５夕（０．００７７ミリモル）を１００泌のホゥ酸
緩衝液（ｐＨ９．２）に溶解した溶液に氷冷下上記活性
化ポリエチレングリコール１．７夕（１．８ミリモル）
を加えた。１時間氷冷下礎洋した後分子量１０方阻止メ
ンプランにより限外渡過を繰返し未反応ヘモグロビンお
よび活性化ポリエチレングリコ、一ルを猿別後乾燥する
ことにより修飾ヘモグロビン２．６夕を得た。
置換度：約５０。実施例 ３ポリエチレングリコ−ルモ
ノメチルエーテル（平均分子量１９００）１９夕（０．
０１モル）、４００Ｍのベンゼン、炭酸ソーダ１０夕お
よび塩化シアヌル５．５夕（０．０３モル）を用いて、
実施例２と同機の反応、処理を行い活性化ポリエチレン
グリコール２４夕を得た。
ノメチルエーテル（平均分子量１９００）１９夕（０．
０１モル）、４００Ｍのベンゼン、炭酸ソーダ１０夕お
よび塩化シアヌル５．５夕（０．０３モル）を用いて、
実施例２と同機の反応、処理を行い活性化ポリエチレン
グリコール２４夕を得た。
ヘモグロビン２夕（０．０３１ミリモル）、２０物‘の
ホウ酸緩衝液（ｐＨ９．２）および活性化ポリエチレン
グリコール６．４夕（３．１ミリモル）を用いて実施例
２と同様の反応、精製操作を行し、疹節ヘモグロビンを
７．６タ得た。置換度：約８０。実施例 ４ポリエチレ
ングリコ一ルモノメチルエーテル（平均分子量５０００
）５０夕（０．０１モル）、５００の‘のベンゼン、１
０夕の炭酸ソーダおよび５．５夕（０．０３モル）の塩
化シアヌルを用いて実施例２と同様の反応、処理を行い
活性化ポリエチレングリコール５３夕を得た。
ホウ酸緩衝液（ｐＨ９．２）および活性化ポリエチレン
グリコール６．４夕（３．１ミリモル）を用いて実施例
２と同様の反応、精製操作を行し、疹節ヘモグロビンを
７．６タ得た。置換度：約８０。実施例 ４ポリエチレ
ングリコ一ルモノメチルエーテル（平均分子量５０００
）５０夕（０．０１モル）、５００の‘のベンゼン、１
０夕の炭酸ソーダおよび５．５夕（０．０３モル）の塩
化シアヌルを用いて実施例２と同様の反応、処理を行い
活性化ポリエチレングリコール５３夕を得た。
１０％ヘモグロビン溶液２０舷、４５０の‘のホウ酸緩
衝液（ｐＨ９．２）および４０夕の活性化ポリＪエチレ
ングリコールを用いて実施例２と同様の反応、精製操作
を行い修飾ヘモグロビン３４夕を得た。
衝液（ｐＨ９．２）および４０夕の活性化ポリＪエチレ
ングリコールを用いて実施例２と同様の反応、精製操作
を行い修飾ヘモグロビン３４夕を得た。
置換度：１０５。実施例 ５
ポリエチレングリコール（平均分子量２００００）Ｚ４
Ｍ（０．００２モル）、ベンゼン１夕、炭酸ソーダ１０
夕および塩化シアヌル１．１夕（０．００６モル）を加
え、室温にて一夜楓拝した。
Ｍ（０．００２モル）、ベンゼン１夕、炭酸ソーダ１０
夕および塩化シアヌル１．１夕（０．００６モル）を加
え、室温にて一夜楓拝した。
石油エーテル１夕を加えて生じた沈澱を用いて実施例２
と同様の反応、処理を行い活性化ポリエチレングリコー
ル３９２夕が得られた。４００の【のホウ酸緩衝液（ｐ
Ｈ９．２）に１０％ヘモグロビン溶液２０の‘（０．０
０００３モル）を加えて氷冷下上記活性化ポリエチレン
グリコール１０夕（０．０００５モル）を加え１時間損
拝を行った。
と同様の反応、処理を行い活性化ポリエチレングリコー
ル３９２夕が得られた。４００の【のホウ酸緩衝液（ｐ
Ｈ９．２）に１０％ヘモグロビン溶液２０の‘（０．０
０００３モル）を加えて氷冷下上記活性化ポリエチレン
グリコール１０夕（０．０００５モル）を加え１時間損
拝を行った。
分子量１０万阻止のメンブランで限外猿過し濃縮後ｐＨ
６．０のリン酸緩衝液で平衡化したＣＭ−セフアデック
スに吸着させた後、ｐＨ６．３のリン酸緩衝液で溶離す
る分画を捨て、次にｐＨ６．８のリン酸緩衝液で漆離す
る分画を分離した。この分画を分子量１０万阻止のメン
ブランで濃縮して修飾ヘモグロビン３夕を得た。置換度
：約４。実施例 ６ ポリエチレングリコールモノステアリルエステル（平均
分子量２５００）１２．５夕（０．００５モル）、４０
０の‘のベンゼン、炭酸ソーダ５夕および塩化シアヌル
２．７５夕（０．０１５モル）を用いて実施例２と同様
の反応、処理を行い活性化ポリエチレングリコール１３
．５夕を得た。
６．０のリン酸緩衝液で平衡化したＣＭ−セフアデック
スに吸着させた後、ｐＨ６．３のリン酸緩衝液で溶離す
る分画を捨て、次にｐＨ６．８のリン酸緩衝液で漆離す
る分画を分離した。この分画を分子量１０万阻止のメン
ブランで濃縮して修飾ヘモグロビン３夕を得た。置換度
：約４。実施例 ６ ポリエチレングリコールモノステアリルエステル（平均
分子量２５００）１２．５夕（０．００５モル）、４０
０の‘のベンゼン、炭酸ソーダ５夕および塩化シアヌル
２．７５夕（０．０１５モル）を用いて実施例２と同様
の反応、処理を行い活性化ポリエチレングリコール１３
．５夕を得た。
１０％ヘモグロビン溶液２５の【（０．０４ミリモル）
、９００の【ホウ酸緩衝液（ｐＨ９．２）および上記活
性化ポリエチレングリコール１０．５夕（０．００４モ
ル）を用いて実施例２と同様の反応、精製操作を行い修
飾ヘモグロビン８夕を得た。
、９００の【ホウ酸緩衝液（ｐＨ９．２）および上記活
性化ポリエチレングリコール１０．５夕（０．００４モ
ル）を用いて実施例２と同様の反応、精製操作を行い修
飾ヘモグロビン８夕を得た。
置換度：約９０。実施例 ７
ポリエチレングリコ一ルモノオレイエーテル（平均分子
量１０００）５夕（０．００５モル）、４００叫のベン
ゼン、炭酸ソーダ５夕および塩化シアヌル２．７５夕（
０．０１５モル）を用いて実施例２と同様の反応、処理
を行い活性化ポリェチレソグＩＪコール６夕を得た。
量１０００）５夕（０．００５モル）、４００叫のベン
ゼン、炭酸ソーダ５夕および塩化シアヌル２．７５夕（
０．０１５モル）を用いて実施例２と同様の反応、処理
を行い活性化ポリェチレソグＩＪコール６夕を得た。
牛ヘモグロビン（シグマ社製）１．３夕（０．０２ミリ
モル）、４５０の‘ホゥ酸緩衝液（ｐＨ９．２）および
上記活性化ポリエチレングリコール５．３夕（０．００
２モル）を用いて実施例２と同様の反応、精製操作を行
い修飾ヘモグロビン４．２夕を得た。置換度：約８を実
施例 ８ ポリプロピレングリコール（平均分子量４０００）１２
夕（０．００３モル）を水１２０舷に溶解し、これに実
施例１と同様の操作により臭化シアン（０．００９５モ
ル）を反応、濃縮を行った。
モル）、４５０の‘ホゥ酸緩衝液（ｐＨ９．２）および
上記活性化ポリエチレングリコール５．３夕（０．００
２モル）を用いて実施例２と同様の反応、精製操作を行
い修飾ヘモグロビン４．２夕を得た。置換度：約８を実
施例 ８ ポリプロピレングリコール（平均分子量４０００）１２
夕（０．００３モル）を水１２０舷に溶解し、これに実
施例１と同様の操作により臭化シアン（０．００９５モ
ル）を反応、濃縮を行った。
豚ヘモグロビン（シグマ社製）２夕を実施例１と同様の
操作で反応させた後、分離、精製を行い修飾へモグ。ピ
ン７夕を得た。ポリプロピレングリコールの置換度は約
３０であった。本発明で得られる化合物、修飾ヘモグロ
ビンについて血管内滞留時間および酸素新和力を調べた
。
操作で反応させた後、分離、精製を行い修飾へモグ。ピ
ン７夕を得た。ポリプロピレングリコールの置換度は約
３０であった。本発明で得られる化合物、修飾ヘモグロ
ビンについて血管内滞留時間および酸素新和力を調べた
。
一試料につきラット（平均体重：３５０夕）二匹を用い
、ラットの体重に対し５の【／ｋ９の４〜６％修飾ヘモ
グロビンを静柱後５分、ＩＣ分、１８分、３０分、６ひ
分、９０分、１２０分経過時に０．５の‘ずつ採血し、
遠心処理後血数中の修飾ヘモグロビン量をシアンメトヘ
モグロビン法により比色定草した。
、ラットの体重に対し５の【／ｋ９の４〜６％修飾ヘモ
グロビンを静柱後５分、ＩＣ分、１８分、３０分、６ひ
分、９０分、１２０分経過時に０．５の‘ずつ採血し、
遠心処理後血数中の修飾ヘモグロビン量をシアンメトヘ
モグロビン法により比色定草した。
そのグラフから注入した修飾ヘモグロビンの血鰍中での
半減期を計算した。結果を表１に示す。表１ 十 実施例１〜４の方法により調製した修飾ヘモグロビン溶
液（０．１Ｍ ＮａＣＩ溶液、ｐＨ７．４０）をＡｍｉ
ｍｏ社製Ｈｅｍ−○−Ｓｃａｎ装置を用い、酸素平衡曲
線を描き、それから５０％酸素解離圧（Ｐ５０値）を求
めた。
半減期を計算した。結果を表１に示す。表１ 十 実施例１〜４の方法により調製した修飾ヘモグロビン溶
液（０．１Ｍ ＮａＣＩ溶液、ｐＨ７．４０）をＡｍｉ
ｍｏ社製Ｈｅｍ−○−Ｓｃａｎ装置を用い、酸素平衡曲
線を描き、それから５０％酸素解離圧（Ｐ５０値）を求
めた。
結果を表２に示す。表２
Claims (1)
- １ 酸素運搬物質を含有する代用血液において、酸素運
搬物質がヘモグロビンと、ポリエチレングリコール、ポ
リプロピレングリコールまたはエチレングリコール−プ
ロピレングリコール共重合体との結合物であることを特
徴とする代用血液。
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54087910A JPS6023084B2 (ja) | 1979-07-11 | 1979-07-11 | 代用血液 |
| GB8022583A GB2055868B (en) | 1979-07-11 | 1980-07-10 | Blood substitute containing hemoglobin |
| US06/167,360 US4301144A (en) | 1979-07-11 | 1980-07-10 | Blood substitute containing modified hemoglobin |
| FR8015568A FR2460674A1 (fr) | 1979-07-11 | 1980-07-11 | Succedane du sang contenant de l'hemoglobine modifiee |
| DE19803026398 DE3026398A1 (de) | 1979-07-11 | 1980-07-11 | Modifiziertes haemoglobin enthaltender blutersatz |
| CA000356067A CA1146858A (en) | 1979-07-11 | 1980-07-11 | Blood substitute containing modified hemoglobin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54087910A JPS6023084B2 (ja) | 1979-07-11 | 1979-07-11 | 代用血液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5612308A JPS5612308A (en) | 1981-02-06 |
| JPS6023084B2 true JPS6023084B2 (ja) | 1985-06-05 |
Family
ID=13928063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54087910A Expired JPS6023084B2 (ja) | 1979-07-11 | 1979-07-11 | 代用血液 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4301144A (ja) |
| JP (1) | JPS6023084B2 (ja) |
| CA (1) | CA1146858A (ja) |
| DE (1) | DE3026398A1 (ja) |
| FR (1) | FR2460674A1 (ja) |
| GB (1) | GB2055868B (ja) |
Families Citing this family (915)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
| JPS58225025A (ja) * | 1982-06-24 | 1983-12-27 | Nippon Chem Res Kk | 効力持続性組成物 |
| JPS5959629A (ja) * | 1982-09-27 | 1984-04-05 | Nippon Chem Res Kk | 効力持続性組成物 |
| JPS59104323A (ja) * | 1982-12-07 | 1984-06-16 | Ajinomoto Co Inc | 代用血液 |
| DE3340592A1 (de) * | 1983-11-10 | 1985-05-23 | B. Braun Melsungen Ag, 3508 Melsungen | Konjugate makromolekularer verbindungen an haemoglobine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
| USRE34271E (en) * | 1984-06-27 | 1993-06-01 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| JPS6153223A (ja) * | 1984-08-22 | 1986-03-17 | Ajinomoto Co Inc | ヘモグロビン−ポリアルキレングリコ−ル結合体の製造方法 |
| DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
| US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5650388A (en) * | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5312808A (en) * | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
| US6172039B1 (en) | 1990-04-16 | 2001-01-09 | Apex Bioscience, Inc. | Expression of recombinant hemoglobin and hemoglobin variants in yeast |
| US5239061A (en) * | 1990-06-20 | 1993-08-24 | Research Corporation Technologies, Inc. | Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin |
| US5248766A (en) * | 1990-08-17 | 1993-09-28 | Baxter International Inc. | Oxirane-modified hemoglobin based composition |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| AU662155B2 (en) | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| US5334705A (en) * | 1991-08-15 | 1994-08-02 | Duke University | Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin |
| AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
| US5344393A (en) * | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
| US6187744B1 (en) | 1992-03-11 | 2001-02-13 | Michael W. Rooney | Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5612310A (en) * | 1993-05-24 | 1997-03-18 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
| US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
| US5840851A (en) * | 1993-07-23 | 1998-11-24 | Plomer; J. Jeffrey | Purification of hemoglobin |
| US5578564A (en) * | 1993-07-23 | 1996-11-26 | Somatogen, Inc. | Nickel-free hemoglobin and methods for producing such hemoglobin |
| US5804561A (en) * | 1993-08-16 | 1998-09-08 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5767089A (en) * | 1993-08-16 | 1998-06-16 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5824781A (en) * | 1993-08-16 | 1998-10-20 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5807831A (en) * | 1993-08-16 | 1998-09-15 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5817632A (en) * | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5725839A (en) * | 1993-08-16 | 1998-03-10 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI |
| TW381022B (en) * | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
| US5741893A (en) * | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5840701A (en) * | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5665869A (en) * | 1993-11-15 | 1997-09-09 | Somatogen, Inc. | Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin |
| US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
| US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| DE69503849T2 (de) * | 1994-03-31 | 1999-04-01 | Amgen Inc., Thousand Oaks, Calif. | Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten |
| US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| US6306454B1 (en) * | 1994-10-17 | 2001-10-23 | Baxter International Inc. | Method for producing improved medical devices and devices so produced |
| US5585484A (en) * | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
| EA001220B1 (ru) | 1995-06-07 | 2000-12-25 | Глаксо Груп Лимитед | Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения |
| US5865784A (en) * | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US7883693B2 (en) | 1995-12-18 | 2011-02-08 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and methods of preparation of use |
| US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
| PT876165E (pt) * | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | Composicoes de polimeros reticulados e processos para a sua utilizacao |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US20050089958A1 (en) * | 1996-01-09 | 2005-04-28 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US20020165157A1 (en) * | 1996-04-01 | 2002-11-07 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
| IL126383A0 (en) * | 1996-04-01 | 1999-05-09 | Genentech Inc | Apo-2li and apo-3 apoptosis polypeptides |
| US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| US20040241645A1 (en) * | 1997-01-31 | 2004-12-02 | Genentech, Inc. | O-fucosyltransferase |
| JP3394540B2 (ja) | 1997-01-31 | 2003-04-07 | ジェネンテク・インコーポレイテッド | Ｏ−フコシルトランスフェラーゼ |
| US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| ATE302019T1 (de) * | 1997-02-28 | 2005-09-15 | Univ California | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
| US20020102706A1 (en) * | 1997-06-18 | 2002-08-01 | Genentech, Inc. | Apo-2DcR |
| WO1999027098A2 (en) | 1997-11-21 | 1999-06-03 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
| DE69832970T2 (de) | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US20100152426A1 (en) * | 1997-05-15 | 2010-06-17 | Ashkenazi Avi J | Apo-2 receptor fusion proteins |
| EP1860187B1 (en) * | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Apo-2 receptor |
| EP1003856A1 (en) | 1997-06-05 | 2000-05-31 | Board of Regents, The University of Texas System | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| JP2002508663A (ja) * | 1997-06-18 | 2002-03-19 | ジェネンテク，インコーポレイテッド | Ａｐｏ−２ＤｃＲ |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| DK1009817T3 (da) * | 1997-08-26 | 2010-01-18 | Genentech Inc | RTD-receptor |
| US20030175856A1 (en) * | 1997-08-26 | 2003-09-18 | Genetech, Inc. | Rtd receptor |
| CA2382409A1 (en) | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PT1015587E (pt) * | 1997-09-18 | 2008-07-31 | Genentech Inc | Polipéptido dcr3, um homólogo de tnfr |
| US20040231011A1 (en) * | 2001-06-28 | 2004-11-18 | Genentech, Inc. | DcR3 polypeptide, a TNFR homolog |
| EP1967587A1 (en) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3 Ligand |
| DE69840051D1 (de) | 1997-10-29 | 2008-11-06 | Genentech Inc | Durch wnt-1 induzierbare gene |
| US6387657B1 (en) | 1997-10-29 | 2002-05-14 | Genentech, Inc. | WISP polypeptides and nucleic acids encoding same |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| EP1045906B1 (en) | 1998-01-15 | 2008-10-15 | Genentech, Inc. | Apo-2 ligand |
| NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
| ES2389387T3 (es) | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Polipéptidos homólogos de VEGF y de BMP1 |
| EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| AU740405B2 (en) | 1998-05-15 | 2001-11-01 | Genentech Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| ATE443723T1 (de) * | 1998-06-12 | 2009-10-15 | Genentech Inc | Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| HK1042114B (zh) | 1998-10-23 | 2006-09-29 | Amgen K-A, Inc. | 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽 |
| EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| CA2450402A1 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting cancer cell growth comprising pro224 |
| EP2319929A1 (en) | 1998-12-23 | 2011-05-11 | Genentech, Inc. | IL-1 related polypeptides |
| JP2000230000A (ja) * | 1999-02-08 | 2000-08-22 | Hokkaido Univ | 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体 |
| CA2266174A1 (en) * | 1999-03-18 | 2000-09-18 | Hemosol Inc. | Hemoglobin-antioxidant conjugates |
| KR100316154B1 (ko) * | 1999-03-26 | 2001-12-12 | 노광 | 폴리에틸렌글리콜－헤모글로빈 결합체 |
| EP1792989A1 (en) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
| IL145775A0 (en) | 1999-04-12 | 2002-07-25 | Agensys Inc | 13 transmembrane protein expressed in prostate cancer |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| AU5152700A (en) | 1999-06-15 | 2001-01-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DE60045201D1 (de) | 1999-08-12 | 2010-12-16 | Agensys Inc | C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens |
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| DK1220913T3 (da) | 1999-10-05 | 2009-03-16 | Agensys Inc | G-protein-koblet-receptor opreguleret i prostatacancer og anvendelser deraf |
| US6180598B1 (en) | 1999-10-07 | 2001-01-30 | Deanna J. Nelson | Covalently modified hemoglobin having low temperature-dependent oxygen-binding function |
| US20030190644A1 (en) | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
| US6893818B1 (en) * | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
| EP1230349B1 (en) | 1999-11-18 | 2007-06-13 | Dendreon Corporation | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| US6703480B1 (en) * | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
| EP1666494A1 (en) | 1999-12-01 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| EP1897944B1 (en) | 1999-12-23 | 2011-08-10 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| AU2048501A (en) | 2000-02-16 | 2001-08-27 | Genentech Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US6740520B2 (en) * | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
| US20040086970A1 (en) * | 2000-03-22 | 2004-05-06 | Genentech, Inc. | Novel cytokine receptors and nucleic acids encoding the same |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2709771A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| DE10031740A1 (de) | 2000-06-29 | 2002-02-14 | Sanguibio Tech Ag | Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung |
| DE10031744A1 (de) | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
| FR2811323B1 (fr) * | 2000-07-07 | 2006-10-06 | Fuma Tech Gmbh | Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication |
| DE60136281D1 (de) | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| ES2311540T3 (es) | 2000-08-28 | 2009-02-16 | Agensys, Inc. | Acido nucleico y proteina correspondiente llamada 85p1b3 util en el tratamiento y deteccion del cancer. |
| EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20020164576A1 (en) * | 2000-09-22 | 2002-11-07 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2 |
| US20020115058A1 (en) * | 2000-09-22 | 2002-08-22 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1 |
| US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
| US6576452B1 (en) | 2000-10-04 | 2003-06-10 | Genencor International, Inc. | 2,5-diketo-L-gluconic acid reductases and methods of use |
| US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| US6747132B2 (en) | 2000-11-29 | 2004-06-08 | Apex Biosciences, Inc. | Methods for the synthesis of a modified hemoglobin solution |
| US20030165878A1 (en) * | 2000-12-22 | 2003-09-04 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of MCM3AP |
| US20030099963A1 (en) * | 2000-12-22 | 2003-05-29 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of TBX21 |
| US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
| US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
| US20030232334A1 (en) * | 2000-12-22 | 2003-12-18 | Morris David W. | Novel compositions and methods for cancer |
| US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
| US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
| AU2002305052A1 (en) | 2001-03-13 | 2002-09-24 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| EP1383884A4 (en) | 2001-03-22 | 2004-12-15 | Dendreon Corp | SERINE PROTEASE CVSP14 CODING NUCLEIC ACID MOLECULES, THE CODED POLYPEPTIDES AND METHODS THEREOF |
| NZ527971A (en) | 2001-03-27 | 2006-03-31 | Dendreon Corp | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| EP2280030A3 (en) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| WO2002092841A2 (en) | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| WO2005010044A2 (en) | 2003-07-08 | 2005-02-03 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| US7019117B2 (en) | 2001-07-19 | 2006-03-28 | Albert Einstein College Of Medicine Of Yeshiva University | Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols |
| CA2453995A1 (en) * | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
| BR0212070A (pt) | 2001-08-29 | 2004-09-28 | Genentech Inc | ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica |
| US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| AU2002336446B2 (en) | 2001-09-06 | 2008-03-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| ES2431929T3 (es) | 2001-09-18 | 2013-11-28 | Genentech, Inc. | Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores |
| US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
| US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| EP1456371A1 (en) * | 2001-12-05 | 2004-09-15 | Dow Global Technologies Inc. | Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications |
| EP2067472A1 (en) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040230380A1 (en) * | 2002-01-04 | 2004-11-18 | Xencor | Novel proteins with altered immunogenicity |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP2110434A1 (en) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Type-1 cytokine receptor GLM-R |
| US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
| EP1490402A4 (en) * | 2002-03-20 | 2007-05-02 | Biopolymed Inc | PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF |
| AU2003218350A1 (en) * | 2002-03-21 | 2003-10-08 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| BR0308710A (pt) * | 2002-03-26 | 2007-01-09 | Biosynexus Inc | conjugados poliméricos antimicrobianos |
| CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7432342B2 (en) | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| MXPA04012243A (es) * | 2002-06-07 | 2005-02-25 | Genentech Inc | Composiciones y metodos para l diagnostico y tratamiento de tumores. |
| JP3912206B2 (ja) * | 2002-07-05 | 2007-05-09 | 株式会社日立製作所 | 筒内直接燃料噴射装置用燃料ポンプ |
| EP1572130A4 (en) | 2002-07-08 | 2008-07-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES |
| US20050043516A1 (en) * | 2002-07-25 | 2005-02-24 | Genentech, Inc. | TACI antibodies and uses thereof |
| CA2495660A1 (en) * | 2002-08-12 | 2004-02-19 | Genencor International, Inc. | Mutant e. coli appa phytase enzymes |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| WO2004019860A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
| US20040091490A1 (en) * | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2004024072A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| EP1578364A4 (en) | 2002-09-16 | 2011-06-08 | Genentech Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM |
| CA2499625A1 (en) | 2002-09-18 | 2004-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of increasing platelet and hematopoietic stem cell production |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| AU2003295401B2 (en) | 2002-11-08 | 2010-04-29 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| AU2002352976B2 (en) | 2002-11-27 | 2007-11-08 | Agensys, Inc. | Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
| WO2004054473A1 (en) * | 2002-12-12 | 2004-07-01 | Baxter International Inc. | Method for producing medical devices and devices so produced |
| CN102319437B (zh) * | 2002-12-26 | 2017-10-13 | 山景医药公司 | 具有增强的生物学效用的干扰素‑β的聚合物缀合物 |
| AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US20040225077A1 (en) * | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| EP2343315A3 (en) | 2003-02-10 | 2011-11-23 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
| US20070218071A1 (en) * | 2003-09-15 | 2007-09-20 | Morris David W | Novel therapeutic targets in cancer |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
| JP2007524362A (ja) | 2003-02-14 | 2007-08-30 | サイグレス ディスカバリー， インコーポレイテッド | 癌における治療ｇｐｃｒ標的 |
| AU2004219592C1 (en) | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| DE602004025332D1 (de) * | 2003-03-14 | 2010-03-18 | Wyeth Corp | Antikörper gegen il21-rezeptor und deren verwendung |
| US7235639B2 (en) * | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| KR101291787B1 (ko) | 2003-05-30 | 2013-08-07 | 어젠시스 인코포레이티드 | 전립선 줄기 세포 항원 (ｐｓｃａ) 변이체 및 그의서브서열 |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| PT2272868E (pt) * | 2003-06-05 | 2015-07-07 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
| US7939058B2 (en) * | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) * | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
| CA2542353A1 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US20070274988A1 (en) * | 2003-10-10 | 2007-11-29 | Five Prime Therapeautics, Inc. | Kiaa0779, Splice Variants Thereof, and Methods of Their Use |
| PL2295073T3 (pl) | 2003-11-17 | 2014-09-30 | Genentech Inc | Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego |
| AU2005205533B2 (en) | 2004-01-07 | 2012-03-22 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specific monoclonal antibody and uses thereof |
| US20050169970A1 (en) * | 2004-02-02 | 2005-08-04 | Unilever Bestfoods, North America | Food composition with fibers |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
| WO2006083260A2 (en) | 2004-04-28 | 2006-08-10 | Angiotech Biomaterials Corporation | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| CA2567883A1 (en) * | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| EP2428522A1 (en) | 2004-05-28 | 2012-03-14 | Agensys, Inc. | Antibodies that bind to PSCA proteins for diagnosis of cancer |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
| US8303973B2 (en) | 2004-09-17 | 2012-11-06 | Angiotech Pharmaceuticals (Us), Inc. | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
| TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CA2581423A1 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| EP1812474B1 (en) | 2004-10-15 | 2010-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006071441A2 (en) | 2004-11-30 | 2006-07-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US20060134698A1 (en) * | 2004-12-20 | 2006-06-22 | Evanston Northwestern Healthcare Research Institute | Methods for treating cardiac disease by modifying an N-terminal domain of troponin I |
| CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2006089106A2 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| BRPI0609655A2 (pt) | 2005-03-31 | 2010-03-16 | Agensys Inc | anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| CA2604885A1 (en) | 2005-04-07 | 2006-10-19 | Guoying Yu | Cacna1e in cancer diagnosis, detection and treatment |
| EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| TWI299257B (en) * | 2005-05-16 | 2008-08-01 | Tung Hai Biotechnology Corp | γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS |
| US20060271262A1 (en) * | 2005-05-24 | 2006-11-30 | Mclain Harry P Iii | Wireless agricultural network |
| WO2008018854A2 (en) * | 2005-06-06 | 2008-02-14 | The Rockefeller University | Bactiophage lysins for bacillus anthracis |
| CA2610709A1 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| US7582291B2 (en) * | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| EP2004695A2 (en) | 2005-07-08 | 2008-12-24 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| EP2295080A3 (en) | 2005-07-25 | 2011-06-22 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| WO2007016240A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | Use of antibody to m-csf |
| WO2007016285A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
| MX2008001706A (es) * | 2005-08-04 | 2008-04-07 | Nektar Therapeutics Al Corp | Conjugados de una porcion g-csf y un polimero. |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| ES2357626T3 (es) * | 2005-08-24 | 2011-04-28 | The Rockefeller University | Lisinas mutantes de ply-gbs. |
| US8691944B2 (en) * | 2005-10-04 | 2014-04-08 | The Research Foundation For The State University Of New York | Fibronectin polypeptides and methods of use |
| WO2007053524A2 (en) * | 2005-10-28 | 2007-05-10 | The Florida International University Board Of Trustees | Horse: human chimeric antibodies |
| EP3023497A1 (en) | 2005-11-18 | 2016-05-25 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| EP1962584A2 (en) | 2005-11-21 | 2008-09-03 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| US9726673B2 (en) * | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
| US9012605B2 (en) | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
| AU2007233263A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
| TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS |
| CA2646611A1 (en) | 2006-03-21 | 2008-05-22 | Genentech, Inc. | Combinatorial therapy |
| KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도 |
| EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
| WO2007149355A2 (en) * | 2006-06-16 | 2007-12-27 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
| US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
| ATE540681T1 (de) | 2006-06-26 | 2012-01-15 | Amgen Inc | Verfahren zur behandlung von atherosklerose |
| JP5406027B2 (ja) * | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | ＥｐｈＢ３特異的抗体およびその使用 |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| CA2664752A1 (en) | 2006-09-29 | 2008-04-03 | F. Hoffmann-La Roche Ag | Antibodies against ccr5 and uses thereof |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP1914303A1 (en) * | 2006-10-09 | 2008-04-23 | Qiagen GmbH | Thermus eggertssonii DNA polymerases |
| CA2667706A1 (en) | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| DK2087002T3 (da) * | 2006-10-27 | 2014-10-27 | Lpath Inc | Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat |
| BRPI0716680A2 (pt) * | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| JP5313909B2 (ja) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | 炎症性疾患および癌の処置のためのチエノピリミジノン |
| RU2447449C2 (ru) | 2006-11-14 | 2012-04-10 | Дженентек, Инк. | Модуляторы нейрональной регенерации |
| JP5537946B2 (ja) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬 |
| KR20140119831A (ko) | 2006-12-07 | 2014-10-10 | 노파르티스 아게 | Ｅｐｈｂ３에 대한 길항제 항체 |
| CN101199856B (zh) * | 2006-12-15 | 2011-04-20 | 天津协和生物科技发展有限公司 | 一种携氧抗休克药物 |
| US7943728B2 (en) | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| US8183201B2 (en) * | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
| JP2010517944A (ja) * | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Ｄｌｌ４シグナリング阻害薬およびその使用 |
| AR065083A1 (es) | 2007-02-02 | 2009-05-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
| AU2008212820B2 (en) | 2007-02-09 | 2014-01-30 | Northwestern University | Particles for detecting intracellular targets |
| US8415453B2 (en) * | 2007-02-13 | 2013-04-09 | Academia Sinica | Lung cancer-targeted peptides and applications thereof |
| US8088887B2 (en) * | 2007-02-13 | 2012-01-03 | Academia Sinica | Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment |
| US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
| CA2682135A1 (en) * | 2007-04-17 | 2008-10-30 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| CA2724432A1 (en) | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| AU2008259907B2 (en) | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| EP2167111A4 (en) * | 2007-06-14 | 2010-06-09 | Univ New York State Res Found | POLYPEPTIDES AND METHOD OF USE |
| ATE543835T1 (de) | 2007-07-16 | 2012-02-15 | Genentech Inc | Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren |
| ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| NZ582794A (en) | 2007-07-26 | 2012-09-28 | Amgen Inc | Modified lecithin-cholesterol acyltransferase enzymes |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| CA2694824A1 (en) * | 2007-08-09 | 2009-02-12 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| EP4248976B1 (en) | 2007-08-23 | 2026-04-22 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| PE20090993A1 (es) | 2007-08-29 | 2009-07-08 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados y derivados de los mismos |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PT2222697E (pt) | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Polipeptídeos imunossupressores e ácidos nucleicos |
| US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
| US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
| CA2709354C (en) | 2007-12-21 | 2014-06-17 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| AU2009206306B2 (en) | 2008-01-25 | 2013-06-06 | Amgen Inc. | Ferroportin antibodies and methods of use |
| PT2247620T (pt) | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| US20100303828A1 (en) | 2008-01-31 | 2010-12-02 | INSERM Institut National de la Sante et de la Recherche Medicale) | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US8697081B2 (en) * | 2008-04-09 | 2014-04-15 | The Regents Of The University Of Michigan | Method of modulating neovascularization |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US8921315B1 (en) | 2008-04-24 | 2014-12-30 | Neumedicines, Inc. | Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12 |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| AU2009246166B2 (en) | 2008-05-15 | 2014-09-18 | Tetherex Pharmaceuticals Corporation | Anti-PSGL-1 antibodies and methods of identification and use |
| US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| MX2010013333A (es) | 2008-06-04 | 2011-04-05 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
| EP2318036B1 (en) | 2008-06-30 | 2015-06-03 | The Regents of the University of Michigan | Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
| US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| KR101442323B1 (ko) | 2008-09-07 | 2014-09-25 | 글라이코넥스 인코포레이티드 | 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도 |
| EP3281955A1 (en) | 2008-10-02 | 2018-02-14 | Aptevo Research and Development LLC | Cd86 antagonist multi-target binding proteins |
| WO2010040766A1 (en) | 2008-10-07 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
| EA032727B1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Мутантный резистентный к протеолизу полипептид fgf21 и его применение |
| BRPI0919564A2 (pt) | 2008-10-22 | 2019-09-24 | Genentech, Inc | modulação da degeneração do axônio |
| US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| NZ592436A (en) * | 2008-11-06 | 2012-10-26 | Glenmark Pharmaceuticals Sa | Treatment with anti-alpha2 integrin antibodies |
| KR20160091440A (ko) | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| DK2365803T3 (en) | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
| CA2747721C (en) * | 2008-12-19 | 2021-07-20 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US20100294952A1 (en) * | 2009-01-15 | 2010-11-25 | Northwestern University | Controlled agent release and sequestration |
| EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| JP6051048B2 (ja) | 2009-03-25 | 2016-12-21 | ジェネンテック， インコーポレイテッド | 新規な抗α５β１抗体及びその使用 |
| SG174891A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Treatment of insulin-resistant disorders |
| CA2757382A1 (en) | 2009-04-01 | 2010-10-21 | Kristi Elkins | Anti-fcrh5 antibodies and immunoconjugates |
| WO2010112034A2 (en) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
| US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| SG175259A1 (en) * | 2009-04-20 | 2011-11-28 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
| EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
| TWI560197B (en) | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
| BRPI1011236A2 (pt) | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
| WO2010148142A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
| NZ597580A (en) * | 2009-07-20 | 2013-11-29 | Univ Nat Taiwan | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof |
| AU2010276160A1 (en) | 2009-07-21 | 2012-02-09 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| KR20120089253A (ko) | 2009-07-31 | 2012-08-09 | 제넨테크, 인크. | Ｂｖ８? 또는 ｇ?ｃｓｆ?길항제를 이용한 종양 전이의 억제 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| EP2488553B1 (en) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN102656266B (zh) * | 2009-10-15 | 2016-08-03 | 霍夫曼-拉罗奇有限公司 | 具有改变的受体特异性的嵌合成纤维细胞生长因子 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| CN104043126A (zh) | 2009-10-22 | 2014-09-17 | 霍夫曼-拉罗奇有限公司 | 轴突变性的调节 |
| BR112012009409A2 (pt) | 2009-10-22 | 2017-02-21 | Genentech Inc | método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra |
| WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| JP5866119B2 (ja) | 2009-10-30 | 2016-02-17 | ノースウェスタン ユニバーシティ | 鋳型ナノ複合体 |
| SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| AR078986A1 (es) | 2009-11-12 | 2011-12-14 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas |
| WO2011062997A2 (en) | 2009-11-17 | 2011-05-26 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
| AU2010321832B2 (en) | 2009-11-20 | 2014-08-14 | Amgen Inc. | Anti-Orai1 antigen binding proteins and uses thereof |
| PE20121584A1 (es) | 2009-11-30 | 2012-11-29 | Genentech Inc | Composiciones y metodos para el diagnostico y el tratamiento de tumores |
| WO2011066511A1 (en) | 2009-11-30 | 2011-06-03 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |
| JP2013512672A (ja) * | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| WO2011075636A2 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Wise binding agents and epitopes |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR20120130752A (ko) | 2009-12-23 | 2012-12-03 | 내셔널 타이완 유니버시티 | 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법 |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| WO2011097527A2 (en) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection of therapeutic moieties using enhanced fc regions |
| US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
| JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン，エルエルシー | Ｈｓａ関連組成物および使用方法 |
| MX2012009809A (es) | 2010-02-23 | 2012-11-23 | Sanofi Sa | Anticuerpos anti - integrina alfa2 y sus usos. |
| NZ601293A (en) | 2010-02-23 | 2014-10-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| JP2013520512A (ja) | 2010-02-25 | 2013-06-06 | サンガート， インコーポレイテッド | 低い反応成分比を用いて、ｐｅｇ−ヘモグロビン結合体を調製するための方法 |
| US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| EP2547355B1 (en) | 2010-03-19 | 2017-01-11 | Baxalta GmbH | Tfpi inhibitors and methods of use |
| NZ602020A (en) | 2010-03-31 | 2014-05-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| US9005580B2 (en) | 2010-04-01 | 2015-04-14 | Oncorena Ab | Treatment of renal cell carcinoma |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| CN102958941A (zh) | 2010-05-03 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 用于肿瘤诊断和治疗的组合物和方法 |
| EP3450432A1 (en) | 2010-05-17 | 2019-03-06 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CA2800348C (en) | 2010-05-18 | 2020-07-21 | Lena A. Basile | Il-12 formulations for enhancing hematopoiesis |
| US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| AU2011268146A1 (en) | 2010-06-17 | 2013-01-10 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
| TW201201840A (en) | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| EP2596025B1 (en) | 2010-07-23 | 2018-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
| CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| WO2012023113A2 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Designer osteogenic proteins |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| EP2619226B1 (en) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| EP3219731A1 (en) | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US9445990B2 (en) | 2010-10-06 | 2016-09-20 | Medtronic, Inc. | TNF inhibitor formulation for use in implantable infusion devices |
| US20120201821A1 (en) | 2010-10-25 | 2012-08-09 | Gonzalez Jr Lino | Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma |
| SG190006A1 (en) | 2010-11-04 | 2013-06-28 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| AU2011349124B2 (en) | 2010-12-21 | 2016-09-15 | Oklahoma Medical Research Foundation | Anti-P-selectin antibodies and methods of their use and identification |
| WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP2668207A4 (en) | 2011-01-24 | 2015-06-10 | Univ Singapore | MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES |
| WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
| TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
| TWI719112B (zh) | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| MX373443B (es) | 2011-03-31 | 2020-05-20 | Inst Nat Sante Rech Med | Anticuerpos dirigidos contra icos y usos de los mismos. |
| US8628773B2 (en) | 2011-04-07 | 2014-01-14 | Amgen Inc. | Antigen binding proteins |
| EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| RS58326B1 (sr) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2012255116B2 (en) | 2011-05-18 | 2017-05-25 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals |
| KR102011924B1 (ko) | 2011-05-18 | 2019-08-21 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| JP2014516960A (ja) | 2011-05-19 | 2014-07-17 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ヒトｈｅｒ３抗体及びその使用 |
| PH12013502489B1 (en) | 2011-06-03 | 2019-04-24 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| KR101969515B1 (ko) | 2011-06-10 | 2019-04-16 | 박스알타 인코퍼레이티드 | 재조합 vwf의 투여에 의한 응고 질환의 치료 |
| US9925246B2 (en) | 2011-06-13 | 2018-03-27 | Neumedicines, Inc. | Mitigation of cutaneous injury with IL-12 |
| EP2723761B1 (en) | 2011-06-23 | 2017-11-08 | The Regents of The University of Michigan | Compound and method for modulating opioid receptor activity |
| EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
| WO2013012855A1 (en) | 2011-07-18 | 2013-01-24 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
| WO2013025479A1 (en) | 2011-08-16 | 2013-02-21 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
| MX2014001736A (es) | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
| EP2750695A2 (en) | 2011-08-31 | 2014-07-09 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| JP2014526517A (ja) | 2011-09-14 | 2014-10-06 | ノースウェスタン ユニバーシティ | 血液脳関門を通過することができるナノ抱合体 |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CA3182462A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| AU2012323849B2 (en) | 2011-10-13 | 2017-04-20 | EyePoint, Inc. | Treatment of ocular disease |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RS67639B1 (sr) | 2011-11-16 | 2026-02-27 | Boehringer Ingelheim Int | Anti il-36r antitela |
| JP2015501639A (ja) | 2011-11-23 | 2015-01-19 | アイジェニカ バイオセラピューティクス インコーポレイテッド | 抗ｃｄ９８抗体およびその使用方法 |
| EP2790714A4 (en) | 2011-12-16 | 2015-08-05 | Kalos Therapeutics Inc | METHODS AND USES OF PEPTIDES SSOCIATED TO ANP (ATRIAL NATRIURETIC PEPTIDE), BNP (NATRIURETIC BRAIN PEPTIDE), AND CNP (NATRIURETIC PEPTIDE TYPE C) AND DERIVATIVES THEREOF FOR THE TREATMENT OF RETINO DISORDERS AND DISEASES |
| EP2793944B1 (en) | 2011-12-23 | 2025-10-08 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| US9616106B2 (en) | 2012-01-18 | 2017-04-11 | Neumedicines, Inc. | IL-12 for radiation protection and radiation-induced toxicity mitigation |
| EP2807187B1 (en) | 2012-01-26 | 2017-07-26 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
| EA025407B1 (ru) | 2012-03-05 | 2016-12-30 | Джилид Калистога Ллс | Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она |
| US9228006B2 (en) | 2012-03-16 | 2016-01-05 | University Health Network | Methods and compositions for modulating Toso activity |
| EP2827883B1 (en) | 2012-03-21 | 2019-05-08 | Baxalta GmbH | Tfpi inhibitors and methods of use |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| WO2013149219A2 (en) | 2012-03-30 | 2013-10-03 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
| AP3908A (en) | 2012-03-30 | 2016-11-24 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases |
| WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
| WO2013155346A1 (en) | 2012-04-11 | 2013-10-17 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| CN104507497B (zh) | 2012-05-03 | 2018-10-19 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
| EP2850095B1 (en) | 2012-05-17 | 2019-10-09 | RA Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| EA201492282A1 (ru) | 2012-06-11 | 2015-07-30 | Амген Инк. | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение |
| JP6429771B2 (ja) | 2012-06-21 | 2018-11-28 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ｃ−Ｍｅｔに結合する抗原結合タンパク質 |
| WO2013192596A2 (en) | 2012-06-22 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind ccr2 |
| EP2864355B1 (en) | 2012-06-25 | 2016-10-12 | Orega Biotech | Il-17 antagonist antibodies |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2013280693B2 (en) | 2012-06-27 | 2018-01-04 | The Trustees Of Princeton University | Split inteins, conjugates and uses thereof |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| US10457733B2 (en) | 2012-08-03 | 2019-10-29 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| EP2892547B1 (en) | 2012-09-10 | 2020-08-12 | Xencor, Inc. | A dominant negative tnf-alpha inhibitor for use in treating neurological disorders of the cns |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| JP2015533832A (ja) | 2012-10-09 | 2015-11-26 | アイジェニカ バイオセラピューティクス インコーポレイテッド | 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法 |
| HRP20170743T1 (hr) | 2012-11-20 | 2017-07-28 | Sanofi | Anti-ceacam5 protutijela i njihova uporaba |
| JP6525456B2 (ja) | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
| EP3444281B1 (en) | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| EP3400961B1 (en) | 2012-12-27 | 2021-02-24 | Sanofi | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| EP2948478B1 (en) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| EP3936521B1 (en) | 2013-03-15 | 2026-02-11 | Xencor, Inc. | Heterodimeric proteins |
| EP2968503B1 (en) | 2013-03-15 | 2018-08-15 | Intrinsic LifeSciences LLC | Anti-hepcidin antibodies and uses thereof |
| DK2968495T3 (da) | 2013-03-15 | 2019-10-14 | Daniel J Capon | Hybrid immunoglobulin indeholdende en ikke-peptid-bro |
| EP2970449B1 (en) | 2013-03-15 | 2019-09-25 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
| US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| PE20151673A1 (es) | 2013-03-15 | 2015-11-27 | Genentech Inc | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO |
| WO2014140368A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza m2 and cd3 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| SG11201508829QA (en) | 2013-05-30 | 2015-12-30 | Biogen Ma Inc | Oncostatin m receptor antigen binding proteins |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CA2916259C (en) | 2013-06-28 | 2024-02-20 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| TWI688401B (zh) | 2013-09-13 | 2020-03-21 | 美商安進公司 | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN105593241B (zh) | 2013-10-04 | 2020-07-10 | 豪夫迈·罗氏有限公司 | 特异性结合her3的抗体 |
| SG11201602460QA (en) | 2013-10-11 | 2016-04-28 | Oxford Biotherapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
| WO2015057583A1 (en) | 2013-10-14 | 2015-04-23 | The United States Of America, As Represented By The Secretary | Treatment of chronic kidney disease with sahps |
| US20160235810A1 (en) | 2013-10-18 | 2016-08-18 | Novartis Ag | Methods of treating diabetes and related disorders |
| CN111443069A (zh) | 2013-10-28 | 2020-07-24 | 多茨技术公司 | 过敏原检测 |
| SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
| WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
| CA2936102A1 (en) | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AU2015218903B2 (en) | 2014-02-20 | 2020-10-15 | Allergan, Inc. | Complement component C5 antibodies |
| KR20160126054A (ko) | 2014-02-27 | 2016-11-01 | 알러간, 인코포레이티드 | 보체 인자 Bb 항체 |
| US20150252434A1 (en) | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| SI3116486T1 (sl) | 2014-03-14 | 2020-07-31 | Biomolecular Holdings Llc | Hibridni imunoglobulin, ki vsebuje nepeptidilno vezavo |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| WO2015158851A1 (en) | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
| FR3020063A1 (fr) | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
| PT3155017T (pt) | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| TWI689520B (zh) | 2014-05-30 | 2020-04-01 | 漢霖生技股份有限公司 | 抗表皮生長因子受體（ｅｇｆｒ）抗體 |
| HUE045646T2 (hu) | 2014-06-12 | 2020-01-28 | Ra Pharmaceuticals Inc | Komplement aktivitás modulálása |
| JP6455995B2 (ja) | 2014-06-13 | 2019-01-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| JP6655074B2 (ja) | 2014-06-20 | 2020-02-26 | ジェネンテック， インコーポレイテッド | シャガシンに基づく足場組成物、方法及び使用 |
| WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| JP6749312B2 (ja) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | 最適化された種間特異的二重特異性単鎖抗体コンストラクト |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| EP3183000A4 (en) | 2014-08-22 | 2018-04-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
| MX382490B (es) | 2014-08-27 | 2025-03-13 | Amgen Inc | Variantes de inhibidor de tejido de metaloproteinasa tipo tres (timp-3), composiciones y metodos |
| WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| ES2727154T3 (es) | 2014-10-24 | 2019-10-14 | Astrazeneca Ab | Combinación |
| US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| CN105669863B (zh) | 2014-12-05 | 2019-09-13 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
| US11220545B2 (en) | 2014-12-08 | 2022-01-11 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| SI3240801T1 (sl) | 2014-12-31 | 2021-04-30 | Checkmate Pharmaceuticals, Inc. | Kombinirana imunoterapija tumorja |
| EP3812398A3 (en) | 2015-01-23 | 2021-07-21 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| SG10202103879YA (en) | 2015-02-04 | 2021-05-28 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| WO2016128349A1 (en) | 2015-02-09 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
| CN108271359B (zh) | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CN113527495A (zh) | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| MX2017012966A (es) | 2015-04-10 | 2018-06-06 | Amgen Inc | Muteinas de interleuquina 2 para la expansion de celulas t regulatorias. |
| DK3283524T3 (da) | 2015-04-17 | 2023-05-30 | Amgen Res Munich Gmbh | BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3 |
| US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| AU2016275149A1 (en) | 2015-06-12 | 2018-01-04 | Georgia State University Research Foundation | Compositions and methods for treating opioid tolerance |
| HUE051165T2 (hu) | 2015-07-29 | 2021-03-01 | Allergan Inc | ANG-2 elleni, csak nehézláncot tartalmazó antitestek |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| CA2992788A1 (en) | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| US20170058038A1 (en) | 2015-09-01 | 2017-03-02 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of lupus nephritis |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| EP3355920A4 (en) | 2015-09-29 | 2019-05-15 | Celgene Corporation | PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF |
| JP7628764B2 (ja) | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | Ａｓｇｒ阻害剤 |
| CA3000697A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
| EP3359575B1 (en) | 2015-10-09 | 2020-07-22 | Florida State University Research Foundation, Inc. | Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| CN108463248B (zh) | 2015-11-12 | 2022-10-21 | 西雅图基因公司 | 聚糖相互作用化合物及使用方法 |
| EP3383497A4 (en) | 2015-12-04 | 2019-06-12 | The Regents of The University of California | NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| EP4218790B1 (en) | 2015-12-16 | 2026-02-18 | UCB Holdings, Inc. | Modulators of complement activity |
| KR102927822B1 (ko) | 2016-01-29 | 2026-02-13 | 주식회사유한양행 | Pd-l1에 결합하는 항원 결합 단백질 |
| CA3011942A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| SG11201805770UA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| US11357849B2 (en) | 2016-03-07 | 2022-06-14 | Musc Foundation For Research Development | Anti-nucleolin antibodies |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| ES2930351T3 (es) | 2016-04-15 | 2022-12-09 | Evive Biotechnology Shanghai Ltd | Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante |
| JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| CN115073581A (zh) | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| AU2017290389B2 (en) | 2016-07-01 | 2024-09-26 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3506925B1 (en) | 2016-09-02 | 2023-09-06 | Christopher J. Soares | Use of cgrp receptor antagonists in treating glaucoma |
| JP2019534858A (ja) | 2016-09-09 | 2019-12-05 | ジェネンテック， インコーポレイテッド | Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 |
| SMT202500445T1 (it) | 2016-09-16 | 2026-01-12 | Shanghai Henlius Biotech Inc | Anticorpi anti-pd-1 per l'uso nel trattamento del cancro |
| WO2018053405A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| US10941195B2 (en) | 2016-10-04 | 2021-03-09 | Fairbanks Pharmaceuticals, Inc. | Anti-follistatin-like 3 antibodies and treatment of diabetes |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| CN110023325B (zh) | 2016-10-14 | 2023-07-04 | 尼优美特里克斯医疗有限公司 | 具有提高的生物活性和降低的对嗜中性粒细胞弹性蛋白酶降解易感性的来源于纤连蛋白的肽 |
| EP3411071A4 (en) | 2016-10-20 | 2019-08-28 | I-Mab | NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF |
| TW202300515A (zh) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| EP4599847A3 (en) | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| AU2017356872A1 (en) | 2016-11-08 | 2019-05-30 | University Of Miami | Anti-secretogranin III (Scg3) antibodies and uses thereof |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| JP7075134B2 (ja) | 2016-12-07 | 2022-05-25 | モレキュラー テンプレーツ，インク． | 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子 |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| EP3571216A4 (en) | 2017-01-19 | 2020-11-04 | The United States of America, as represented by the Secretary, Department of Health and Human Services | APOC-II MIMETIC PEPTIDES |
| AU2018214223B2 (en) | 2017-02-02 | 2025-08-14 | Amgen Inc. | Low pH pharmaceutical composition comprising T cell engaging antibody constructs |
| WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
| EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| US10729741B2 (en) | 2017-03-27 | 2020-08-04 | Neomatrix Therapeutics Inc. | Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury |
| US20180273627A1 (en) | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| EP4230649A3 (en) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
| KR102700015B1 (ko) | 2017-05-05 | 2024-08-29 | 암젠 인크 | 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물 |
| EP3634466A4 (en) | 2017-06-06 | 2021-03-24 | Relinia, Inc. | MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS |
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| PT3648787T (pt) | 2017-07-07 | 2025-01-20 | Takeda Pharmaceuticals Co | Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante |
| DK3648788T3 (da) | 2017-07-07 | 2024-08-19 | Takeda Pharmaceuticals Co | Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf |
| WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| US10947295B2 (en) | 2017-08-22 | 2021-03-16 | Sanabio, Llc | Heterodimers of soluble interferon receptors and uses thereof |
| WO2019070086A2 (en) * | 2017-09-20 | 2019-04-11 | RIM, Chang Ho | BLOOD SUBSTITUTE CARRYING OXYGEN OBTAINED FROM PORK BLOOD AND METHOD OF MAKING SAME |
| CA3079313A1 (en) | 2017-11-02 | 2019-05-09 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| BR112020009136A2 (pt) | 2017-11-14 | 2020-10-13 | Arcellx, Inc. | polipeptídeos que contêm domínio d e usos dos mesmos |
| TWI827570B (zh) | 2017-12-11 | 2024-01-01 | 美商安進公司 | 雙特異性抗體產品之連續製造製程 |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
| CN111886246B (zh) | 2017-12-29 | 2024-12-17 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| FI3735295T3 (fi) | 2018-01-03 | 2024-11-20 | Mederis Diabetes Llc | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon |
| SG11202006259SA (en) | 2018-01-26 | 2020-08-28 | Genentech Inc | Il-22 fc fusion proteins and methods of use |
| LT3743088T (lt) | 2018-01-26 | 2022-12-27 | F. Hoffmann-La Roche Ag | Il-22 fc kompozicijos ir jų naudojimo būdai |
| CN111971301B (zh) | 2018-01-31 | 2025-01-07 | 艾莱克特有限责任公司 | 抗ms4a4a抗体及其使用方法 |
| EP3752194A4 (en) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| EP3752195A4 (en) | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | FELINE MCDONOUGH'S SARCOMA (FMS) -LIKE TYROSINKINASE-3 RECEPTOR LIGANDS (FLT3L) ANTIBODIES AND USES THEREOF IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
| JP2021514354A (ja) | 2018-02-21 | 2021-06-10 | ジェネンテック， インコーポレイテッド | ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与 |
| CA3090305A1 (en) | 2018-02-28 | 2019-09-06 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| BR112020014591A2 (pt) | 2018-03-14 | 2020-12-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | anticorpos anticlaudina 18.2 |
| CN117003874A (zh) | 2018-03-20 | 2023-11-07 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| SG11202009213TA (en) | 2018-03-21 | 2020-10-29 | Baxalta Inc | Separation of vwf and vwf propeptide by chromatographic methods |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| US12103972B2 (en) | 2018-04-06 | 2024-10-01 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof |
| CN112334485B (zh) | 2018-04-06 | 2024-09-27 | 百进生物科技公司 | 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法 |
| SG11202009647VA (en) | 2018-04-09 | 2020-10-29 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| WO2019211665A1 (en) | 2018-04-30 | 2019-11-07 | Takeda Pharmaceutical Company Limited | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof |
| US11065336B2 (en) | 2018-04-30 | 2021-07-20 | Medimmune Limited | Conjugates for targeting and clearing aggregates |
| US12084489B2 (en) | 2018-05-02 | 2024-09-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection |
| MX2020011828A (es) | 2018-05-25 | 2021-02-09 | Alector Llc | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN119613548A (zh) | 2018-06-13 | 2025-03-14 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| AU2019289646B2 (en) | 2018-06-18 | 2025-10-23 | Innate Pharma | Compositions and methods for treating cancer |
| EP3807321A4 (en) | 2018-06-18 | 2022-03-02 | Anwita Biosciences, Inc. | ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF |
| AU2019288496B2 (en) | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| AU2019291890A1 (en) | 2018-06-29 | 2020-12-17 | Boehringer Ingelheim International Gmbh | Anti-CD40 antibodies for use in treating autoimmune disease |
| CN119912569A (zh) | 2018-06-29 | 2025-05-02 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
| MY208638A (en) | 2018-07-02 | 2025-05-21 | Amgen Inc | Anti-steap1 antigen-binding protein |
| PT3618928T (pt) | 2018-07-13 | 2023-03-29 | Alector Llc | Anticorpos anti-sortilina e métodos de utilização dos mesmos |
| WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
| CA3107186A1 (en) | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
| WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| WO2020047326A2 (en) | 2018-08-31 | 2020-03-05 | ALX Oncology Inc. | Decoy polypeptides |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| CN113365697B (zh) | 2018-09-25 | 2024-07-19 | 百进生物科技公司 | 抗tlr9药剂和组合物及其制备方法和使用方法 |
| TW202028237A (zh) | 2018-09-27 | 2020-08-01 | 美商西建公司 | SIRPα結合蛋白及其使用方法 |
| EP3856773A1 (en) | 2018-09-28 | 2021-08-04 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| AR117650A1 (es) | 2018-10-11 | 2021-08-18 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecíficos |
| US12227548B2 (en) | 2018-11-19 | 2025-02-18 | Dana-Farber Cancer Institute, Inc. | Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses |
| US12257340B2 (en) | 2018-12-03 | 2025-03-25 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| JP7499257B2 (ja) | 2019-01-04 | 2024-06-13 | リゾルブ セラピューティクス， エルエルシー | ヌクレアーゼ融合タンパク質によるシェーグレン病の処置 |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| BR112021015068A2 (pt) | 2019-02-01 | 2021-10-05 | Takeda Pharmaceutical Company Limited | Métodos de tratamento profilático usando vwf recombinante (rvwf) |
| SG11202107843WA (en) | 2019-02-07 | 2021-08-30 | Sanofi Sa | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| EP3693023A1 (en) | 2019-02-11 | 2020-08-12 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| WO2020176771A1 (en) | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| WO2020191365A1 (en) | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| CN114096559B (zh) | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| US11180561B2 (en) | 2019-04-09 | 2021-11-23 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies |
| US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| JP2022531113A (ja) | 2019-04-30 | 2022-07-06 | ギガジェン，インコーポレイティッド | 組換えポリクローナルタンパク質およびその使用方法 |
| AU2020267874A1 (en) | 2019-05-09 | 2021-10-28 | Boehringer Ingelheim International Gmbh | Anti-Sema3A antibodies and their uses for treating eye or ocular diseases |
| US12558398B2 (en) | 2019-06-04 | 2026-02-24 | Ucb Holdings, Inc. | Inflammatory disease treatment with complement inhibitors |
| AU2020290573B2 (en) | 2019-06-13 | 2026-01-29 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
| TWI877179B (zh) | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| CA3143087A1 (en) | 2019-07-03 | 2021-01-07 | Arnima BISHT | Antibodies and methods of use |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| WO2021022083A2 (en) | 2019-07-31 | 2021-02-04 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| US20220281967A1 (en) | 2019-08-02 | 2022-09-08 | Orega Biotech | Novel il-17b antibodies |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| UY38836A (es) | 2019-08-13 | 2021-02-26 | Amgen Inc | Muteínas de interleucina-2 para la expansión de células t reguladoras |
| TW202123965A (zh) | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| US20220306741A1 (en) | 2019-09-10 | 2022-09-29 | Amgen Inc. | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity |
| JP2022547556A (ja) | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法 |
| CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| TWI859339B (zh) | 2019-09-24 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| JP7678802B2 (ja) | 2019-11-04 | 2025-05-16 | アレクトル エルエルシー | Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法 |
| CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
| JP2023505169A (ja) | 2019-12-03 | 2023-02-08 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質 |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| MX2022006787A (es) | 2019-12-05 | 2022-07-19 | Sorrento Therapeutics Inc | Composiciones y metodos que comprenden un anticuerpo anti-cd47 en combinacion con un anticuerpo dirigido al tumor. |
| AU2020401319A1 (en) | 2019-12-13 | 2022-06-30 | Alector Llc | Anti-MerTK antibodies and methods of use thereof |
| CN114867749A (zh) | 2019-12-17 | 2022-08-05 | 安进公司 | 用于疗法中的双重白介素-2/tnf受体激动剂 |
| WO2021119827A1 (en) | 2019-12-19 | 2021-06-24 | Transfert Plus, Société En Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
| JP2023525423A (ja) | 2020-01-15 | 2023-06-16 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｐｒａｍｅに特異的に結合する抗原結合タンパク質 |
| WO2021146383A1 (en) | 2020-01-17 | 2021-07-22 | BioLegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
| WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| EP4093513A4 (en) | 2020-01-24 | 2024-05-08 | Dana-Farber Cancer Institute, Inc. | Uses of biomarkers for improving immunotherapy |
| BR112022015326A2 (pt) | 2020-02-04 | 2022-10-11 | Takeda Pharmaceuticals Co | Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante |
| WO2021164744A1 (en) | 2020-02-19 | 2021-08-26 | Evive Biotechnology (Shanghai) Ltd | Methods for treating graft versus host disease |
| CN115485300A (zh) | 2020-02-26 | 2022-12-16 | 索伦托药业有限公司 | 具有通用掩蔽部分的可活化的抗原结合蛋白 |
| EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| WO2021195089A1 (en) | 2020-03-23 | 2021-09-30 | Sorrento Therapeutics, Inc. | Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof |
| EP4126937A1 (en) | 2020-03-31 | 2023-02-08 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
| WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| BR112022020753A2 (pt) | 2020-04-15 | 2022-12-20 | Voyager Therapeutics Inc | Compostos de ligação a tau |
| WO2021216547A1 (en) | 2020-04-20 | 2021-10-28 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US12312412B2 (en) | 2020-05-19 | 2025-05-27 | Amgen Inc. | MAGEB2 binding constructs |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| MA59827B1 (fr) | 2020-05-26 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Anticorps anti-pd-1 |
| AU2021281554A1 (en) | 2020-05-29 | 2022-12-15 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3 |
| CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
| EP4169949A4 (en) | 2020-06-23 | 2024-08-21 | Jiangsu Kanion Pharmaceutical Co., Ltd. | ANTI-CD38 ANTIBODY AND ITS USE |
| WO2021263166A1 (en) | 2020-06-26 | 2021-12-30 | Sorrento Therapeutics, Inc. | Anti-pd1 antibodies and uses thereof |
| EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
| WO2022012680A1 (en) | 2020-07-16 | 2022-01-20 | Nanjing Legend Biotech Co., Ltd. | Cd20 binding molecules and uses thereof |
| WO2022031576A1 (en) | 2020-08-03 | 2022-02-10 | Janssen Biotech, Inc. | Materials and methods for multidirectional biotransportation in virotherapeutics |
| WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
| MX2023002330A (es) | 2020-09-04 | 2023-03-21 | Merck Patent Gmbh | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. |
| JP2023542678A (ja) | 2020-09-21 | 2023-10-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症状態の処置のための抗ｃｄ４０抗体の使用。 |
| US20230381293A1 (en) | 2020-10-14 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Stabilized norovirus virus-like particles as vaccine immunogens |
| US20220127344A1 (en) | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
| WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
| WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
| AU2021374036A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| CA3200317A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
| KR20230098335A (ko) | 2020-11-06 | 2023-07-03 | 암젠 인크 | 클리핑 비율이 감소된 항원 결합 도메인 |
| MX2023005323A (es) | 2020-11-06 | 2023-05-19 | Amgen Inc | Construcciones polipeptidicas que se unen a cd3. |
| US12564642B2 (en) | 2020-11-10 | 2026-03-03 | Sanofi | CEACAM5 antibody-drug conjugate formulation |
| US12171806B2 (en) | 2021-09-28 | 2024-12-24 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists |
| JP2023554382A (ja) | 2020-12-16 | 2023-12-27 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| JP2024502832A (ja) | 2020-12-31 | 2024-01-23 | アラマー バイオサイエンシーズ， インコーポレイテッド | 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法 |
| US20250282870A1 (en) | 2021-01-20 | 2025-09-11 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
| EP4284828A1 (en) | 2021-01-28 | 2023-12-06 | Talem Therapeutics LLC | Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof |
| WO2022170008A2 (en) | 2021-02-05 | 2022-08-11 | Boehringer Ingelheim International Gmbh | Anti-il1rap antibodies |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| EP4308606A1 (en) | 2021-03-18 | 2024-01-24 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
| JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体 |
| KR20230162798A (ko) | 2021-03-26 | 2023-11-28 | 압큐로, 인크. | 항-klrg1 항체 |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| CN115141276A (zh) | 2021-03-31 | 2022-10-04 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
| WO2022212836A1 (en) | 2021-04-01 | 2022-10-06 | Pyxis Oncology, Inc. | Gpnmb antibodies and methods of use |
| AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
| WO2022234102A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
| CA3218692A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| EP4351732A1 (en) | 2021-06-09 | 2024-04-17 | Evotec International GmbH | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
| JP2024527262A (ja) | 2021-06-16 | 2024-07-24 | アレクトル エルエルシー | 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法 |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| CA3227742A1 (en) | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| EP4440594A2 (en) | 2021-11-29 | 2024-10-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| JP2024545428A (ja) | 2021-12-02 | 2024-12-06 | サノフイ | 癌治療における患者選択のためのｃｅａアッセイ |
| JP2024545427A (ja) | 2021-12-02 | 2024-12-06 | サノフイ | Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法 |
| PE20250390A1 (es) | 2021-12-22 | 2025-02-11 | Boehringer Ingelheim Int | Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares |
| UY40097A (es) | 2022-01-07 | 2023-07-14 | Johnson & Johnson Entpr Innovation Inc | Materiales y métodos de proteínas de unión a il-1b |
| EP4489791A1 (en) | 2022-03-09 | 2025-01-15 | Merck Patent GmbH | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| CN119487076A (zh) | 2022-03-09 | 2025-02-18 | 默克专利股份公司 | 抗ceacam5抗体及其缀合物和用途 |
| EP4504761B1 (en) | 2022-04-04 | 2026-02-04 | SwiftPharma BV | Recombinant spider silk-reinforced collagen proteins produced in plants and the use thereof |
| IL316597A (en) | 2022-05-12 | 2024-12-01 | Amgen Res Munich Gmbh | Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity |
| US20260053913A1 (en) | 2022-06-10 | 2026-02-26 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| EP4554969A1 (en) | 2022-07-15 | 2025-05-21 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
| CN119301155A (zh) | 2022-07-19 | 2025-01-10 | 百进生物科技公司 | 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法 |
| MA71628A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Anticorps anti-gpnmb et leurs méthodes d'utilisation |
| WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
| JP2025531814A (ja) | 2022-09-08 | 2025-09-25 | ジーマックス バイオファーム エルエルシー | Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用 |
| JP2025533434A (ja) | 2022-09-14 | 2025-10-07 | アムジエン・インコーポレーテツド | 二重特異性分子安定化組成物 |
| US20260092121A1 (en) | 2022-10-14 | 2026-04-02 | Talem Therapeutics Llc | Anti-trkb/cd3 antibodies and uses thereof |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| EP4615480A1 (en) | 2022-11-07 | 2025-09-17 | Alector LLC | Uses of siglec-9 ecd fusion molecules in cancer treatment |
| US20240226313A1 (en) | 2022-11-17 | 2024-07-11 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
| WO2024126294A1 (en) | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection |
| WO2024126289A1 (en) | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection |
| WO2024126293A1 (en) | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection |
| WO2024147934A1 (en) | 2023-01-06 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Anti-cd38 antibodies for the treatment of autoimmune diseases |
| JP2026503002A (ja) | 2023-01-06 | 2026-01-27 | アレクトル エルエルシー | 抗ｉｌ１８結合タンパク質抗体及びその使用方法 |
| WO2024213635A1 (en) | 2023-04-12 | 2024-10-17 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection |
| EP4720123A1 (en) | 2023-05-25 | 2026-04-08 | Biolegend, Inc. | Ceacam6 binding antibodies and antigen-binding fragments thereof |
| EP4727655A1 (en) | 2023-06-14 | 2026-04-22 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| CN121712788A (zh) | 2023-06-14 | 2026-03-20 | 马里亚纳肿瘤学公司 | 靶向dll3的肽及其构建体 |
| MX2025014635A (es) | 2023-06-14 | 2026-02-03 | Amgen Inc | Moleculas captadoras de enmascaramiento de celulas t |
| US20250034210A1 (en) | 2023-06-14 | 2025-01-30 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| AU2024300235A1 (en) | 2023-07-27 | 2026-01-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| TW202515895A (zh) | 2023-08-15 | 2025-04-16 | 美商吉加根公司 | 靶向ｂ型肝炎病毒（ｈｂｖ）之重組多株蛋白及其使用方法 |
| WO2025037108A2 (en) | 2023-08-15 | 2025-02-20 | Board Of Trustees Of The Leland Stanford Junior University | Modified thrombopoietin |
| CN121816366A (zh) | 2023-09-27 | 2026-04-07 | 百进公司 | 抗gpc4抗体 |
| WO2025072726A1 (en) | 2023-09-29 | 2025-04-03 | Trex Bio, Inc. | Tnf-alpha variant fusion molecules |
| WO2025074337A1 (en) | 2023-10-06 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Use of anti-sirp-alpha antibodies to treat a liver disease or disorder |
| WO2025074328A1 (en) | 2023-10-06 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Use of anti-sirp-alpha antibodies to treat cancer |
| US20250186541A1 (en) | 2023-11-27 | 2025-06-12 | Mariana Oncology Inc. | Dll3 targeting peptides and constructs thereof |
| WO2025122615A1 (en) | 2023-12-05 | 2025-06-12 | Mariana Oncology Inc. | Enriched and stable radioligand therapy formulations and pharmaceutical compositions comprising same |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
| WO2025147696A1 (en) | 2024-01-05 | 2025-07-10 | Resolve Therapeutics, Llc | Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents |
| WO2025155843A1 (en) | 2024-01-19 | 2025-07-24 | Akero Therapeutics, Inc. | Method of treating liver or lung injury |
| TW202600175A (zh) | 2024-02-15 | 2026-01-01 | 德商馬克專利公司 | 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物 |
| US12600770B2 (en) | 2024-03-01 | 2026-04-14 | Boehringer Ingelheim International Gmbh | Antibodies to connective tissue growth factor (CTGF) and uses thereof |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| TW202602929A (zh) | 2024-03-21 | 2026-01-16 | 美商思進公司 | Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途 |
| WO2025210264A1 (en) | 2024-04-04 | 2025-10-09 | Merck Patent Gmbh | Antibody-drug-conjugates binding napi2b |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
| WO2025242845A1 (en) | 2024-05-22 | 2025-11-27 | Merck Patent Gmbh | Colorectal cancer treatment |
| WO2025254987A1 (en) | 2024-06-03 | 2025-12-11 | Alector Llc | Siglec-9 ecd fusion molecule variants and methods of use thereof |
| WO2026024904A1 (en) | 2024-07-24 | 2026-01-29 | Gigagen, Inc. | Custom recombinant polyclonal proteins and methods of use thereof |
| WO2026033259A1 (en) | 2024-08-05 | 2026-02-12 | Lys Therapeutics | Antibodies for treating neurological and neurovascular disorders |
| WO2026072990A1 (en) | 2024-09-27 | 2026-04-02 | Abcuro, Inc. | Methods of treating t-cell large granular lymphocytic leukemia |
| WO2026082894A1 (en) | 2024-10-17 | 2026-04-23 | Sanofi | Ceacam5 antibody-drug conjugate for use in cancer therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
| CA1055932A (en) * | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
-
1979
- 1979-07-11 JP JP54087910A patent/JPS6023084B2/ja not_active Expired
-
1980
- 1980-07-10 GB GB8022583A patent/GB2055868B/en not_active Expired
- 1980-07-10 US US06/167,360 patent/US4301144A/en not_active Expired - Lifetime
- 1980-07-11 FR FR8015568A patent/FR2460674A1/fr active Granted
- 1980-07-11 CA CA000356067A patent/CA1146858A/en not_active Expired
- 1980-07-11 DE DE19803026398 patent/DE3026398A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2055868A (en) | 1981-03-11 |
| US4301144A (en) | 1981-11-17 |
| JPS5612308A (en) | 1981-02-06 |
| GB2055868B (en) | 1983-04-07 |
| FR2460674B1 (ja) | 1983-06-24 |
| FR2460674A1 (fr) | 1981-01-30 |
| CA1146858A (en) | 1983-05-24 |
| DE3026398A1 (de) | 1981-03-26 |
| DE3026398C2 (ja) | 1990-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4301144A (en) | Blood substitute containing modified hemoglobin | |
| CA1055932A (en) | Blood substitute based on hemoglobin | |
| US5478805A (en) | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions | |
| Blakeslee et al. | Immunofluorescence using dichlorotriazinylaminofluorescein (DTAF) I. Preparation and fractionation of labelled IgG | |
| US4385169A (en) | Reactive alpha amino acid polymer | |
| Hughes-Jones | Functional affinity constants of the reaction between 125I-labelled C1q and C1q binders and their use in the measurement of plasma C1q concentrations | |
| JPH026337B2 (ja) | ||
| JPH0684312B2 (ja) | 生体特異性ポリマー | |
| DK164741B (da) | Fremgangsmaade til chromatografisk fraktionering af plasmaproteiner, samt albumin med hoej renhed opnaaet ved fremgangsmaaden | |
| JPS6289630A (ja) | ヘモグロビン―ポリオキシアルキレン結合体 | |
| JPH01157000A (ja) | 凝固因子の単離方法およびそれに適した吸着剤 | |
| CA1106841A (en) | Activated matrix and method of activation | |
| JPH04506030A (ja) | 化学生成物 | |
| Gyenes et al. | PREPARATION AND EVALUATION OF POLYSTYRENE–ANTIGEN CONJUGATES FOR THE ISOLATION OF ANTIBODIES | |
| JPS5853757A (ja) | 免疫アフイニテイクロマトグラフイ−用吸着体及びその製法 | |
| CN109369913B (zh) | 接枝疏水性氨基酸的pH响应性聚天冬氨酸及制备方法 | |
| JPH06319968A (ja) | 血液透析用の透析膜 | |
| CN106040196B (zh) | 一种凝血因子ⅷ亲和层析树脂的制备方法 | |
| JPS6040891B2 (ja) | 砒素捕集材 | |
| US6737524B2 (en) | Activated polyethylene glycol compounds | |
| JPS59104323A (ja) | 代用血液 | |
| JPS59159827A (ja) | 細胞毒性物質を結合した反応性重合体の製造法 | |
| JPH0149299B2 (ja) | ||
| JPS5989629A (ja) | 代用血液 | |
| JPH05285381A (ja) | 低比重リポタンパク質吸着材 |